A study to characterize the humoral immune response to seasonal influenza vaccination in Multiple Sclerosis patients treated with high-efficacy DMTs
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Cladribine (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 14 Dec 2021 New trial record
- 15 Oct 2021 Preliminary results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis